Shares of Mankind Pharma slipped 2.15% to ₹2,477.00 in early trade on Wednesday after the company reported weaker-than-expected quarterly earnings. The stock had closed at ₹2,531.40 in the previous session.
The Delhi-based pharmaceutical firm posted a 10% year-on-year decline in consolidated net profit for Q4 FY25 at ₹424.65 crore, down from ₹476.59 crore in the same quarter last year. While revenue from operations surged 27% YoY to ₹3,079 crore from ₹2,422 crore, the market was disappointed by margin performance.
EBITDA for the quarter stood at ₹686 crore compared to ₹589 crore last year. However, EBITDA margin contracted to 22.3% from 24.3%, falling short of analyst expectations. The company also issued margin guidance for FY26 that was below Street estimates.
Vice-Chairman and Managing Director Rajeev Juneja attributed revenue growth to strong traction in chronic therapies, recovery in the consumer segment, and the consolidation of Bharat Serums and Vaccines (BSV). Mankind’s domestic market share rose from 4.4% in March 2024 to 4.8% in March 2025, driven by growth in the gynaecology segment.
Despite revenue momentum, concerns over profitability and guidance led to negative investor sentiment on Wednesday.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
